Li Yi, Chen Ming, Zhao Yanpeng, Li Ming, Qin Yong, Cheng Shi, Yang Yanyu, Yin Pengbin, Zhang Licheng, Tang Peifu
Department of Orthopedics, General Hospital of Chinese PLA, Beijing, China.
National Clinical Research Center for Orthopedics, Sports Medicine & Rehabilitation, Beijing, China.
Front Pharmacol. 2020 Jul 8;11:1016. doi: 10.3389/fphar.2020.01016. eCollection 2020.
The age-related loss of skeletal muscle, sarcopenia, is characterized by progressive loss of muscle mass, reduction in muscle strength, and dysfunction of physical performance. It has become a global health problem leading to several adverse outcomes in the ageing population. Research on skeletal muscle loss prevention and treatment is developing quickly. However, the current clinical approaches to sarcopenia are limited. Recently, novel drug delivery systems offer new possibilities for treating aged muscle loss. Herein, we briefly recapitulate the potential therapeutic targets of aged skeletal muscle and provide a concise advance in the drug delivery systems, mainly focus on the use of nano-carriers. Furthermore, we elaborately discuss the prospect of aged skeletal muscle treatment by nanotechnology approaches.
与年龄相关的骨骼肌流失,即肌肉减少症,其特征是肌肉质量逐渐丧失、肌肉力量下降以及身体机能障碍。它已成为一个全球性的健康问题,在老年人群中导致了多种不良后果。预防和治疗骨骼肌流失的研究正在迅速发展。然而,目前针对肌肉减少症的临床方法有限。最近,新型药物递送系统为治疗老年肌肉流失提供了新的可能性。在此,我们简要概述老年骨骼肌的潜在治疗靶点,并简要介绍药物递送系统的进展,主要侧重于纳米载体的应用。此外,我们还详细讨论了通过纳米技术方法治疗老年骨骼肌的前景。